DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Benzinga Newsdesk 1 week ago
BiotechGeneralNews
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
- Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation
- Interim Analysis Results Expected in Q1 2027